TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14618048

Group type: EXPERIMENTAL
Intervention: Aortic fat pad removal
Number of subjects: 320

Group type: COMPARATOR
Intervention: Aortic fat pad intact
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Overall incidence of atrial arrhythmias
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Fat pad status in extension study
Number of subjects: 320
Study: 10745855

Group type: EXPERIMENTAL
Intervention: Multi-cell pulsating dynamic mattress system
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 198
Study: 9373421

Group type: EXPERIMENTAL
Intervention: Specialist in-patient (DDU)
Number of subjects: 186

Group type: COMPARATOR
Intervention: General psychiatric (GEN)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Follow-up for ex-DDU patients
Number of subjects: 186

Group type: COMPARATOR
Intervention: Follow-up for ex-GEN patients
Number of subjects: 186
Study: 8336224

Group type: EXPERIMENTAL
Intervention: Midazolam (.35 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diazepam (.70 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (Midazolam, Diazepam, Placebo)
Number of subjects: 90
Study: 3534348

Group type: EXPERIMENTAL
Intervention: Dexamethasone (IV 16 mg 1/2 hr before and 8 mg at 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Metoclopramide (IV 2 mg/kg 1/2 hr before and 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Metoclopramide plus Dexamethasone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and dexamethasone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall response to antiemetic agents
Number of subjects: 52
Study: 31427072

Group type: EXPERIMENTAL
Intervention: Patient code status (do-not-resuscitate or do-not-intubate)
Number of subjects: 194
Study: 29590698

Group type: EXPERIMENTAL
Intervention: Standardised cooling and compression therapy with the Cryo/Cuff™‐system (3 × 10 min twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional cooling therapy
Number of subjects: 50
Study: 26928670

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Celecoxib 800 mg/day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 24572997

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg intravenously over 2 hours)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (normal saline 5 mL/kg intravenously)
Number of subjects: 196
Study: 22650326

Group type: COMPARATOR
Intervention: Nemonoxacin 125 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 250 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (multiple doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (fed conditions)
Number of subjects: 36
Study: 20306554

Group type: EXPERIMENTAL
Intervention: Raltegravir 200, 400, or 600 mg b.i.d. plus optimized background therapy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo b.i.d. plus optimized background therapy
Number of subjects: 178
Study: 18310400

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carefully selected pharmacological therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological history and coping mechanisms understanding
Number of subjects: 0
Study: 16322138

Group type: EXPERIMENTAL
Intervention: Early Start program (home visitation)
Number of subjects: 443
Study: 12588019

Group type: EXPERIMENTAL
Intervention: 2TU PPD prepared by the Guindy laboratory (Dilution-G)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: 2TU PPD prepared by the SSI (Dilution-S)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: 1TU and 2TU Dilution-G
Number of subjects: 1525

Group type: COMPARATOR
Intervention: 1TU PPD RT23 with Tween 80
Number of subjects: 1525
Study: 10583708

Group type: EXPERIMENTAL
Intervention: Intravenous Mg load with 0.1 mmol Mg-aspartate hydrochloride per kilogram bodyweight for 1 hour.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo group receiving no Mg medication.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline Mg values measured by atomic absorption spectroscopy (AAS) in serum and urine.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Femur Mg concentration measured by AAS.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Correlation of femur Mg concentration and %Ret.
Number of subjects: 34
Study: 8561763

Group type: EXPERIMENTAL
Intervention: Supportive treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Behavioral treatment
Number of subjects: 74
Study: 1796932

Group type: EXPERIMENTAL
Intervention: Tertiary care facilities
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nontertiary care facilities
Number of subjects: 74
Study: 6198313

Group type: EXPERIMENTAL
Intervention: Radiation followed by chemotherapy (sequential)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Chemotherapy with temporary interruption for radiation (sandwich)
Number of subjects: 65
Study: 30773722

Group type: EXPERIMENTAL
Intervention: Vitamin D-supplemented yogurt drink (300 IU day-1)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Plain yogurt drink (placebo group)
Number of subjects: 416
Study: 29504498

Group type: EXPERIMENTAL
Intervention: High-dose inhaled glucocorticoids (fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at early signs of loss of asthma control.
Number of subjects: 254

Group type: COMPARATOR
Intervention: Low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) continued.
Number of subjects: 254
Study: 26474541

Group type: EXPERIMENTAL
Intervention: Implant sites with <2 mm of keratinized mucosa (Narrow Group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Implant sites with ≥2 mm of keratinized mucosa (Wide Group)
Number of subjects: 80
Study: 23883550

Group type: EXPERIMENTAL
Intervention: One-question screener
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Four-item FFQ
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Thirty-six-item fish questionnaire
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison of all methods
Number of subjects: 59
Study: 23634566

Group type: EXPERIMENTAL
Intervention: Semi-erect position (Group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Supine position (Group B, Control)
Number of subjects: 76
Study: 18692428

Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Number of subjects: 45
Study: 17463113

Group type: EXPERIMENTAL
Intervention: Quadriceps-sparing technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard arthrotomy
Number of subjects: 120
Study: 15139955

Group type: EXPERIMENTAL
Intervention: Diode laser application (809 nm, 140 mJ, 50 Hz, Ø 600 micro m fibre, contact mode, absorber, 1 min)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical fluoride varnish (0.1 mg, Duraphat) for 6 h
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined application of laser and fluoride varnish
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 80
Study: 11374763

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (AN69) membrane (n = 19)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cellulose acetate (CA) membrane (n = 23)
Number of subjects: 42
Study: 9589293

Group type: EXPERIMENTAL
Intervention: 1 g mesalamine enema
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 2 g mesalamine enema
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 4 g mesalamine enema
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 8060581

Group type: EXPERIMENTAL
Intervention: High NaCl diet (342 mmol/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low NaCl diet (34 mmol/day)
Number of subjects: 31
Study: 2972628

Group type: EXPERIMENTAL
Intervention: Short interval regimen (10 micrograms of Merck Sharp & Dohme recombinant HB vaccine at 0, 2, and 6 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Recommended interval regimen (0, 1, and 6 months)
Number of subjects: 53
Study: 29751850

Group type: EXPERIMENTAL
Intervention: Stabilization exercises on the transversus abdominis and lumbar multifidus muscles
Number of subjects: 29

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 29
Study: 28247490

Group type: EXPERIMENTAL
Intervention: 12-week school-based educational preventive programme
Number of subjects: 401
Study: 26648712

Group type: EXPERIMENTAL
Intervention: Aerobic training (continuous and interval sessions)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study: 23146293

Group type: EXPERIMENTAL
Intervention: ranolazine, 375 mg bid for 3 weeks (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo bid for 3 weeks (group 3)
Number of subjects: 30
Study: 21946094

Group type: EXPERIMENTAL
Intervention: Intraoperative acceleromyography monitoring
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional qualitative train-of-four monitoring
Number of subjects: 155
Study: 19364687

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 50,000 units weekly for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Severely deficient patients (25[OH]D <10 ng/mL) treated in an unblinded fashion
Number of subjects: 100
Study: 16129567

Group type: EXPERIMENTAL
Intervention: Behavioral risk-reduction intervention trial
Number of subjects: 598
Study: 15242697

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11095487

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (Premarin), 0.625 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Droloxifene, 60 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment for 4 weeks)
Number of subjects: 10
Study: 9050018

Group type: EXPERIMENTAL
Intervention: Noradrenaline (i.v. infusion at doses of 10-160 ng/kg/min)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Noradrenaline (i.v. infusion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tyramine (i.v. infusion at doses of 5-20 micrograms/kg/min)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tyramine (i.v. infusion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Atropine (1.5 micrograms/kg i.v. loading dose followed by 0.15 microgram/kg/min i.v. infusion)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Doxazosin (2 mg p.o.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Yohimbine (15 mg p.o.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bisoprolol (15 mg p.o.)
Number of subjects: 2
Study: 8189112

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 11712
Study: 3522114

Group type: EXPERIMENTAL
Intervention: Silver acetate chewing gum
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 28777054

Group type: EXPERIMENTAL
Intervention: Exercise-only group (n = 20)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Compression and exercise group (n = 20)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Compression therapy group (n = 20)
Number of subjects: 78
Study: 27087510

Group type: EXPERIMENTAL
Intervention: Qualitative point‐of‐care device screening for hCGβcf concentrations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quantification of intact hCG, hCGβcf, hCGβ, and specific gravity
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation analysis of specific gravity with intact hCG, hCGβ, and hCGβcf
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Observation of hCGβcf concentrations during gestation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Analysis of individual patterns of hCGβcf excretion
Number of subjects: 100
Study: 24292894

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Baseline aggression
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reduced physiological responsiveness/lower electrodermal reactivity to ATD
Number of subjects: 15
Study: 22644646

Group type: EXPERIMENTAL
Intervention: Internet-based self-management (IBSM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 90
Study: 20637377

Group type: EXPERIMENTAL
Intervention: PCT+ (procalcitonin result revealed to the attending physician)
Number of subjects: 384

Group type: COMPARATOR
Intervention: PCT- (procalcitonin result not revealed)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: PCT strategy to treat all patients with PCT of 0.5 ng/mL or greater
Number of subjects: 384
Study: 16703004

Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study: 15849470

Group type: EXPERIMENTAL
Intervention: Urgent laparoscopic cholecystectomy (ULC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Elective laparoscopic cholecystectomy (ELC)
Number of subjects: 75
Study: 11991610

Group type: EXPERIMENTAL
Intervention: Induction therapy (5 MU interferon-alpha2b daily for 4 weeks followed by 5 MU TIW for 44 weeks)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Noninduction therapy (5 MU interferon-alpha2b TIW for 48 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Noninduction therapy
Number of subjects: 135
Study: 10207209

Group type: EXPERIMENTAL
Intervention: Geriatric in-patient rehabilitation
Number of subjects: 55
Study: 7879724

Group type: EXPERIMENTAL
Intervention: Taped therapeutic suggestions
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Taped music
Number of subjects: 66

Group type: COMPARATOR
Intervention: Blank tapes (Control)
Number of subjects: 66
Study: 2141082

Group type: EXPERIMENTAL
Intervention: 5 mL of 1% etidocaine applied to the banded portion of each fallopian tube after laparoscopic tubal ligation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study: 363995

Group type: EXPERIMENTAL
Intervention: Naloxone (20 microgram/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (0.20 ml/kg)
Number of subjects: 43
Study: 31331574

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a + sesame oil (0.5 ml/kg/day for 6 months)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Interferon beta-1a (30 μg/week)
Number of subjects: 93
Study: 28177744

Group type: EXPERIMENTAL
Intervention: Hot exposure (33 °C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold exposure (7 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room temperature exposure (20 °C)
Number of subjects: 12
Study: 26370414

Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (within 20 seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred cord clamping (after at least 2 minutes)
Number of subjects: 0
Study: 24377608

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (multiple approaches including face‐to‐face interviews, telephone counselling, educational materials, group counselling, individual counselling by trained medical social workers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (general awareness training on tobacco hazards and anti‐tobacco leaflet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21286885

Group type: EXPERIMENTAL
Intervention: Intervention group (30 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 patients)
Number of subjects: 60
Study: 19671933

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 99231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99231
Study: 17152004

Group type: EXPERIMENTAL
Intervention: EPI schedule (IPV at 6, 10, and 14 weeks)
Number of subjects: 455

Group type: COMPARATOR
Intervention: US schedule (IPV at 2, 4, and 6 months)
Number of subjects: 455
Study: 15966502

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 65
Study: 12209104

Group type: EXPERIMENTAL
Intervention: 12‐mm chambers
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6‐mm chambers
Number of subjects: 30
Study: 10496359

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 600 mg m(‐2) day 1 and 8 i.v., 5‐fluorouracil 600 mg m(‐2) day 1 and 8 i.v., methotrexate 40 mg m(‐2) day 1 and 8 i.v., monthly for 6 cycles)
Number of subjects: 116

Group type: COMPARATOR
Intervention: MM (methotrexate 30 mg m(‐2), mitoxantrone 6.5 mg m(‐2), both i.v. day 1 3‐weekly for 8 cycles)
Number of subjects: 116

Group type: COMPARATOR
Intervention: MM
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CMF and MM
Number of subjects: 116
Study: 9097707

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus infection
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pneumocystis carinii infection
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Kaposi's sarcoma
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Non‐Hodgkin's lymphoma
Number of subjects: 55
Study: 1761875

Group type: EXPERIMENTAL
Intervention: Oral midazolam 7.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7034164

Group type: EXPERIMENTAL
Intervention: Trimipramine, 25 mg at night + antacids 20 ml 1 and 3 h after meals
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cimetidine, 400 mg at night + antacids 20 ml 1 and 3 h after meals
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cimetidine, 1000 mg/day + antacids 20 ml 1 and 3 h after meals
Number of subjects: 93
Study: 30877684

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study: 28209728

Group type: EXPERIMENTAL
Intervention: ALDHbr cells
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 25362864

Group type: EXPERIMENTAL
Intervention: DA-1229 2.5 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DA-1229 5 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DA-1229 10 mg
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DA-1229 (all doses)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DA-1229
Number of subjects: 158
Study: 25692840

Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Number of subjects: 18144

Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 18144
Study: 22465522

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 75
Study: 19141621

Group type: EXPERIMENTAL
Intervention: Group affirmation (high identification condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Out-group derogation (high identification condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-affirmation (not specified if high or low identification)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activism to change group behavior (low identification condition)
Number of subjects: 0
Study: 17456124

Group type: EXPERIMENTAL
Intervention: Pamphlet with added information about NSAID interactions and ceiling effects
Number of subjects: 137

Group type: COMPARATOR
Intervention: FDA pamphlet (control)
Number of subjects: 137
Study: 15081625

Group type: EXPERIMENTAL
Intervention: Personalized scripts of traumatic situations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized scripts of abandonment situations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized neutral scripts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diastolic blood pressure and heart rate measures
Number of subjects: 0
Study: 12204314

Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice daily, n=53)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Imipramine (75 mg twice daily, n=56)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 109

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 109
Study: 9718229

Group type: EXPERIMENTAL
Intervention: Metrifonate (AChE inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7648385

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms twice daily
Number of subjects: 556

Group type: COMPARATOR
Intervention: Albuterol 180 micrograms four times daily
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo (plus as-needed albuterol)
Number of subjects: 556
Study: 2559485

Group type: EXPERIMENTAL
Intervention: LMW‐heparinoid (n = 97)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (n = 99)
Number of subjects: 196
Study: 692379

Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methysergide (3 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31929138

Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study: 31187207

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) ingestion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (healthy children without LcS exposure)
Number of subjects: 18
Study: 29195999

Group type: EXPERIMENTAL
Intervention: Raisin consumption (90g/d)
Number of subjects: 36